新的抗癌中药枫苓合剂的主要药效学

Pharmacodynamic studies of the new anticancer Chinese traditional drug-Fengling mixture

目的研究枫苓合剂体内抗癌作用及其他有关药理,为临床试验提供基础。方法采用对人体肿瘤移植的裸鼠体内人体胃癌MKN及人体肝癌QGY的抑制,对荷瘤和正常动物免疫功能的影响及与化学合成药合并用药等方面进行枫苓合剂的主要药效学研究。结果枫苓合剂对人体胃癌MKN 3个剂量组口服给药抑癌率分别为:74．68％-86．76％,49．86％- 59．31％及19．12％-21．68％;腹腔给药抑癌率分别为:78．72％-85．42％,55．32％-62．50％及26．69％-41．67％。对肝癌QGY口服给药抑癌率分别为:47．69％-49．33％,31．94％-33．63％及20．0％-26．0％。对荷Lewis肺癌小鼠显示提高机体NK细胞活力,有明显促进小鼠腹腔巨噬细胞的吞噬功能。对S180肉瘤的生长抑制,单独用环磷酰胺(CTX)15 mg·kg-1抑瘤率为45．16％,与枫苓合剂25 mL·kg-1合并用药抑瘤率为71．29％。结论高剂量枫苓合剂具有高的抗胃癌MKN的作用和中度的抗肝癌QGY的药效,且可提高免疫力,与CTX合用有增效作用。

AIM To study the anti-cancer effects and other relative pharmacology of Fengling mixture in vivo, which provide basis for clinical trials. METHODS Pharmaeodynamie studies of Fengling mixture by methods for determination of the inhibiton rate against human tumor xenograft model of human gastric carcinoma MKN and human hepatoma QGY, the interference on immune efficacy of organism and combined administration with chemical synthetic drug were described. RESULTS Anti-cancer effects of Fengling mixture for human gastric carcinoma MKN by po, the three dosages of inhibition rate were： 74.68 % - 86.76%, 49.86% - 59.31% and 19.12% - 21.68 %, repectively, ip administration were： 78.72 % - 85.42 %, 55.32 % - 62.50 % and 26.69 % - 41.67 %, respectively. For human hepatoma QGY by po administration were 47.69 % - 49.33 %, 31.94 % - 33.63 % and 20.0 % - 26.0 % respectively. It increased the NK cell activity in mice bearing Lewis lung cancer and promoted the phagocytosis of mice intraperitioneal macrophage significantly.The inhibition rate of CTX（15 mg·kg^-1）on tumor S180 is 45.16% ,the CTX combine with Fengling mixture （25 mL·kg^-1）were 71.29%. CONCLUSION High dosage of Fengling mixture shows a high anti-cancer effect for human gastric carcinoma MKN and moderate effect for human hepatoma QGY and it can increase the immune efficacy of organism. It combines with CTX possess synergetie effect.